Dianthus Therapeutics (DNTH) Operating Leases (2022 - 2025)

Dianthus Therapeutics has reported Operating Leases for 4 years, with the latest figure at $1.0 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases fell 12.98% year-over-year to $1.0 million; the trailing twelve-month figure through Dec 2025 stood at $1.0 million (down 12.98% YoY), and the FY2025 full-year result was $1.0 million, down 12.98% from the prior year.
• Operating Leases for Q4 2025 stood at $1.0 million, down from $1.1 million in the prior quarter.
• The five-year high for Operating Leases was $32.4 million in Q1 2022, with the low at $30000.0 in Q2 2024.
• Average Operating Leases over 4 years is $7.5 million, with a median of $1.1 million recorded in 2025.
• Year-over-year, Operating Leases sank 99.05% in 2023 and soared 3630.0% in 2025.
• Tracing DNTH's Operating Leases over 4 years: stood at $438000.0 in 2022, then plunged by 61.64% to $168000.0 in 2023, then soared by 597.02% to $1.2 million in 2024, then retreated by 12.98% to $1.0 million in 2025.
• The last three Operating Leases figures came in at $1.0 million (Q4 2025), $1.1 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.

Peer Comparison